news in brief

US FDA bans APIs made by Fleming Labs

By Gareth Macdonald contact

- Last updated on GMT

US FDA bans APIs made by Fleming Labs

Related tags: Pharmaceutical drug

Fleming Laboratories has been banned from shipping APIs to the US by the FDA which says its manufacturing plant in Nawabpet, Telangana in India is not up to code.

The US regulator banned the drug and active pharmaceutical ingredient (API) firm this week, issuing it a 66-40 import alert. A 66-40 alert is issued when a firm is “not operating in conformity with current good manufacturing practices (GMP's).

The Nawabpet plant – also called Unit I - is about 40km outside Hyderabad. It produces a range of drug ingredients, including anti-histamines, muscle relaxants and treatments for cardiac disorders.

The news comes less than a year​ after Fleming paid outstanding registration fees that had earned the facility a US Food and Drug Administration (FDA) in 2014​. 

Related news

Related products

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

TCC TB – a new filler for direct compression

TCC TB – a new filler for direct compression

Jungbunzlauer | 09-Oct-2017 | Technical / White Paper

TCC TB is a tricalcium citrate tetrahydrate designed to function as a direct compression excipient. It combines exceptional compression characteristics,...

Related suppliers

Follow us

Products

View more

Webinars